1. Introduction {#Section1}
===============

Esophageal cancer is one of the most aggressive cancer types in China [@B1] and across the world [@B2], and esophageal squamous cell carcinoma (ESCC) is the most common pathological subtype. As the development of preoperative new adjuvant therapy, postoperative adjuvant therapy and enhanced recovery after surgery (ERAS), the surgery-based comprehensive treatment model has improved the prognosis of esophageal cancer in the past decades [@B3], [@B4]. However, the 5-year survival rate was still not satisfied, which only ranged from 15% to 25% [@B5]. It has been reported that weight loss, malnutrition and cachexia prevailed in most patients with esophageal cancer [@B6]. Malnutrition could impact the short-term and long-term clinical outcomes of esophageal cancer patients, such as surgical complications and poor survival [@B7]. Thus, nutritional management plays an important role in the treatment process [@B8].

Nutritional screening and assessment are indispensable to guide rational nutritional treatment. Nutrition risk screening (NRS 2002) was the first international evidence-based nutritional screening tool [@B9]. Since the 1970s, many nutritional assessment tools emerged, such as the patient generated-subjective global assessment (PG-SGA) tool [@B10], mini nutritional assessment (MNA) tool [@B11] and malnutrition universal screening tool (MUST) [@B12]. However, these tools were limited to their inevitable subjective assessments. By contrast, nutritional assessment tools based on objective indexes could reflect the nutritional status more accurately, such as the prognostic nutritional index (PNI) [@B13], controlling nutritional status (CONUT) [@B14], and geriatric nutritional risk index (GNRI) [@B15] and so on.

So far, there is no preoperative nutritional assessment tool specifically designed for ESCC patients. Therefore, we designed a retrospective study to propose a novel nutritional scoring tool and a prognostic nomogram for ESCC patients.

2. Materials and methods {#Section2}
========================

2.1. Study population {#Section2.1}
---------------------

Patients who received esophagectomy from Jan. 1^st^, 2004 to Dec. 31, 2016 in the Department of Thoracic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine were consecutively included. The clinical and pathological information of these patients were collected. The inclusion and exclusion criteria were as follow: [@B1] more than 18 years old; [@B2] pathologically diagnosed as ESCC; [@B3] had no history of other malignancies; [@B4] had complete preoperative laboratory test information and height and weight information. The pathological staging of the tumor was conducted according to the American Joint Commission on Cancer/Union for International Cancer Control (AJCC/UICC 8^th^ version) tumor-node-metastasis (TNM) staging manuals [@B16]. All patients were enrolled with written informed consent under institutional review board-approved protocols of the First Affiliated Hospital, Zhejiang University School of Medicine. This study was performed in accordance with the principles of Declaration of Helsinki.

The follow-up information was collected from the outpatient clinical system, as well as the regular telephone follow-up. The last follow-up time was January 2018. The follow-up time ranged from 1.9 months to 134.0 months, and the mean follow-up time was 35.1 months.

2.2. Statistically analysis {#Section2.2}
---------------------------

The cohort was randomly divided into the training set and validation set in ratio 4:1 by SPSS software and the initial seed was 20180101. The cut-off values of continuous variables were determined by the X-tile software (<http://www.tissuearray.org/rimmlab>) and by the minimal P value approach [@B17]. Univariate and multivariate Cox regression analyses were conducted to screen potential risk indexes for ESCC, and the results were shown in the form of hazard ratios (HRs) and their 95% confidence intervals (CIs). The survival difference was assessed by the log rank tests and Kaplan-Meier curves. A new nutritional scoring tool was proposed, and the indexes were selected for both statistical and clinical consideration [@B18]. A nutritional tool-based nomogram was further constructed. Harrell\'s concordance index (C-index), which ranged from 0.5 (denotes random splitting) to 1.0 (perfect prediction), was adopted to assess the discrimination efficacy [@B19]. Besides, bootstrap technique with 1000 repetitions was used for internal and external validation and to calculate the 95% CIs [@B18], [@B20]. Akaike information criterion (AIC) was used to assess the predictive efficacy, and smaller AIC values represent more accurate prognostic stratification [@B21]. The detail definition of PNI, GNRI and CONUT assessment tools was shown in the Supplementary Methods.

All analyses were conducted using the SPSS 22.0 software (IBM SPSS Inc. United States), and R software version 3.2.2 (The R Foundation for Statistical Computing) with the rms, survival and hmisc statistical packages. Statistical significance was set at P \< 0.05 (All P values presented were 2-sided).

3. Results {#Section3}
==========

3.1. Characteristics of included patients {#Section3.1}
-----------------------------------------

A total of 510 ESCC patients were enrolled in this study and there were 408 cases of training set and 102 cases of validation set. The baseline characteristics of included cases were shown in Table [1](#T1){ref-type="table"}. The training set was selected to construct a new scoring tool, and the validation set was selected to test the prognostic model. Continuous variables were converted to categorical variables by X-tile software, as shown in Supplementary Figure [1](#SM0){ref-type="supplementary-material"}.

3.2. Indexes selection by univariate and multivariate Cox regression analyses {#Section3.2}
-----------------------------------------------------------------------------

Univariate Cox regression analysis was performed in the training set population, and the results suggested that gender (P=0.008), smoking (P=0.038), surgical approach (P=0.042), T stage (P\<0.001), N stage (P\<0.001), white blood cell (P=0.022), lymphocyte (P=0.036), triglyceride (P=0.004), uric acid (P=0.016) and BMI (P=0.016) were significantly associated with the prognosis of ESCC patients, as shown in Table [2](#T2){ref-type="table"}. All these statistically significant indexes were further included in the multivariate Cox regression analysis. It suggested that gender (P=0.003), T stage (P=0.005), N stage (P\<0.001), white blood cell (P=0.015), lymphocyte (P=0.030) and uric acid (P=0.007) were independent prognostic factors for ESCC patients.

For both statistical and clinical consideration, the indexes which were selected in the scoring tool had to meet the following criteria: [@B1] it should be statistically significant at least in the univariate Cox regression analysis; [@B2] it could reflect the patients\' nutritional or metabolic status. Finally, BMI, lymphocyte count, uric acid level, and triglyceride level were selected to construct a new BLUT (BMI-lymphocyte-uric acid-triglyceride) nutritional assessment tool.

3.3. Definition and simplification of BLUT nutritional assessment tool {#Section3.3}
----------------------------------------------------------------------

The weight of each index was assessed by the Cox regression model, which was based on the visualization of a nomogram, as shown in Figure [1](#F1){ref-type="fig"}A and Table [3](#T3){ref-type="table"}. Indexes were given different risk scores and divided into the positive risk and negative risk categories. According to the weight scores of the four indexes, each patient was given a total score and a Kaplan-Meier curve was conducted, as shown in Supplementary Figure [2](#SM0){ref-type="supplementary-material"}. The log rank test suggested the BLUT tool had significant prognostic performance in ESCC patients (P=0.049). However, this tool was complicated in this form and lacked of clinical practicability.

Thus, a simplified definition of BLUT tool was proposed based on the number of indexes in positive risk category, as shown in Table [4](#T4){ref-type="table"}. If there was no index in the positive risk category, it was defined as normal. If there was 1 index, or there were 2 indexes or ≥3 indexes in the positive risk category, it was defined as low, moderate and high malnutrition risk, respectively. The Kaplan-Meier curve of the simplified tool was shown in Figure [1](#F1){ref-type="fig"}B, with a log rank P value \<0.001. Subgroup analysis was further conducted in those patients with positive lymph nodes and BLUT showed significant prognostic value for those receiving post-surgery treatment, as shown in the Supplementary Table [1](#SM0){ref-type="supplementary-material"} and Supplementary Figure [3](#SM0){ref-type="supplementary-material"}.

3.4. Comparison of PNI, GNRI, CONUT and BLUT assessment tools {#Section3.4}
-------------------------------------------------------------

The prognostic efficacy of PNI, GNRI, CONUT and BLUT assessment tools in ESCC patients was compared, as shown in Figure [2](#F2){ref-type="fig"} and Table [5](#T5){ref-type="table"}. The cut-off value of PNI was defined by the X-tile analysis, as shown in the Supplementary Figure [4](#SM0){ref-type="supplementary-material"}. The log rank P values of PNI, CONUT and GNRI were 0.153, 0.098 and 0.174, respectively, indicating limited prognostic performance. The univariate analysis indicated that BLUT was significantly associated with the prognosis of ESCC (P\<0.001). In addition, the multivariate Cox regression analysis also suggested that BLUT was an independent prognostic factor for ESCC patients (P=0.003), as shown in Table [6](#T6){ref-type="table"}. Compared with PNI, CONUT and GNRI, the BLUT assessment tool had more rational population distribution in different malnutrition risk categories, and also suggested better predictive accuracy.

3.5. A clinical nomogram based on preoperative nutritional assessment {#Section3.5}
---------------------------------------------------------------------

In order to further analyze the prognostic value of the BLUT tool and to build a precise nutritional assessment-based model, a clinical nomogram based on gender, T stage, N stage and the BLUT tool was proposed, as shown in Figure [3](#F3){ref-type="fig"}A. The nomogram suggested good prognostic performance in both training set (log rank P\<0.001) and validation set (log rank P=0.024), as shown in Figure [3](#F3){ref-type="fig"}B and [3](#F3){ref-type="fig"}C. The C-index and 95% CI of the nomogram was 0.735(0.698-0.772), and the AIC value was 1864.76. It had good prognostic efficacy and was significantly better than the model based on T stage and N stage (P=0.038), as shown in Table [7](#T7){ref-type="table"}. Compared with other nutritional assessment based model, BLUT based nomogram had the highest C-index and the smallest AIC value, which further indicated that BLUT tool based model had more accurate discriminatory utility. The calibration curve of internal validation suggested that the BLUT based model had a high degree of similarity with the real situation in judging the 1-year, 3-year, and 5-year survival status, as shown in Supplementary Figure [5](#SM0){ref-type="supplementary-material"}A, 5B and 5C. The external validation results also suggested good fitting effect (Supplementary Figure [5](#SM0){ref-type="supplementary-material"}D, 5E and 5F), indicating that the BLUT score based ESCC prognosis model could be applied to other population cohorts.

4. Discussion {#Section4}
=============

The study proposed a new BLUT nutritional assessment tool by rigorous index selection and tool simplification, and also compared the prognostic performance between BLUT tool and traditional nutritional assessment tools, including PNI, CONUT and GNRI. In addition, a BLUT-based clinical nomogram was further proposed, which was significantly better than the T stage and N stage based model.

The prognostic value of PNI (log rank P=0.153), CONUT (log rank P=0.098) and GNRI (log rank P=0.174) in ESCC patients was limited. In contrast, BLUT assessment tool was an independent prognostic factor for ESCC patients, which had more rational population distribution in different malnutrition risk categories and better predictive accuracy. Besides, the simplification process enabled BLUT as a simple, convenient and efficient nutritional assessment tool, which could be easily applied in clinical practice. Clinicians could quickly distinguish the preoperative malnutrition risk of ESCC patients by counting the number of indexes in positive risk intervals. On the other hand, a nutritional tool based clinical nomogram could help clinicians precisely predict the prognosis of ESCC patients. The complementarity of the two aspects can help to make quick and accurate clinical decisions.

PNI tool was firstly proposed by Onodera et al. [@B13] in 1984, which was based on 189 digestive tract cancer patients with malnutrition and received parenteral nutrition treatment. Although several studies have proved that PNI could predict the prognosis of ESCC patients who received surgery [@B22]-[@B24], it should be noted that the cut-off value of PNI was controversial [@B24] and its independent prognostic role in ESCC patients was not determined [@B22]. CONUT was proposed by Ignacio et al. [@B14], which included 53 patients from various clinical departments in the hospital. Toyokawa et al. [@B25] conducted a retrospective study based on 185 resectable thoracic ESCC patients and proved its independent prognostic value. However, the sample size of high-CONUT group and low-CONUT group was 17 and 168, respectively. Yoshida et al. [@B26], [@B27] suggested CONUT could be used to predict postoperative morbidity and long term survival of ESCC patients. The imbalanced population distribution in each category also emerged, with only 22 of total 373 cases in the moderate and severe risk category. GNRI was proposed by Yamada et al. [@B28], and the target population was 422 patients receiving continuous hemodialysis. This tool was popularized to 181 elderly hospitalized elderly people (age\>65 years old) by Bouillanne et al. [@B15]. It has been reported by Bo et al. [@B29] that GNRI was an independent prognostic factor for overall survival in elderly ESCC patients with radiotherapy. However, there is no study focusing on the prognostic value of GNRI in preoperative ESCC patients without age restriction. PNI, CONUT and GNRI had a common index of albumin level, while most of the preoperative ESCC patients included in the current study had a normal range of albumin level. 97.6% of the training set population had a normal range (35-55g/L), as shown in Supplementary Figure [6](#SM0){ref-type="supplementary-material"}. The prognostic value of the albumin based scoring tool might be limited under this circumstance. Furthermore, in the univariate Cox analysis, the HRs and 95% Cis for Mckeown approach and Ivor-Lewis approach were 0.491(0.281-0.860) and 0.353(0.632-1.178) compared with Sweet approach, while there were no statistically significant results for these surgical approaches in the multivariate analysis. Many previous studies tried to find the optimal surgical approach for esophageal cancer, however, there was no definite conclusion for this question [@B30].

The current BLUT assessment tool adopted BMI, lymphocyte, uric acid and triglyceride as indexes, taking both general condition of the patients and laboratory tests into account. It has been reported that higher BMI was a protective factor for esophageal cancer [@B31], [@B32]. Lymphocyte is one of the most commonly used nutritional markers [@B13], [@B14] and its metabolism and behavior could be impacted by nutritional status [@B33], [@B34]. Besides, lymphopenia is an independent prognostic factor for ESCC patients [@B35]. The association between uric acid and tumor was controversial. Kuhn et al. [@B36] reported there was a negative association between uric acid and cancer mortality. There were few studies on the relationship between preoperative triglyceride level and prognosis of ESCC, but it was proved as a protective factor in breast cancer patients [@B37]. More well-designed prospective studies with large sample size were warranted in the future to further prove the prognostic role of uric acid and triglyceride in ESCC patients with surgery.

This single-center retrospective study also had some limitations. The BLUT tool was only applicable to ESCC patients who received cancer-directed surgery. The applicability was not yet clear for advanced stage patients who cannot undergo surgery, and for patients who received neoadjuvant therapy before surgery and the laboratory tests were severely impacted. In addition, more researches are required to further confirm whether the scoring system is suitable for continuous monitoring of nutritional status after surgery.

5. Conclusion {#Section5}
=============

The BULT scoring tool could distinguish the heterogeneity of preoperative nutritional status for ESCC patients, especially for those with normal albumin level. Besides, the BLUT-based nomogram had good prognostic efficacy.

Supplementary Material {#SM0}
======================
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###### 

Baseline characteristics of included ESCC patients.

  Variable                          Total cohort(n=510)   Training set(n=408)   Validation set(n=102)                 
  --------------------------------- --------------------- --------------------- ----------------------- -------- ---- --------
  **Gender**                                                                                                          
  Male                              444                   87.06%                355                     87.01%   89   87.25%
  Female                            66                    12.94%                53                      12.99%   13   12.75%
  **Age(years)**                                                                                                      
  ≤59                               157                   30.78%                143                     35.05%   14   13.73%
  60-69                             248                   48.63%                192                     47.06%   56   54.90%
  ≥70                               105                   20.59%                82                      20.10%   23   22.55%
  **Alcohol**                                                                                                         
  No                                178                   34.90%                146                     35.78%   32   31.37%
  Yes                               332                   65.10%                262                     64.22%   70   68.63%
  **Smoking**                                                                                                         
  No                                164                   32.16%                130                     31.86%   34   33.33%
  Yes                               346                   67.84%                278                     68.14%   68   66.67%
  **Education**                                                                                                       
  Primary school and below          309                   60.59%                242                     59.31%   67   65.69%
  Middle school and above           201                   39.41%                166                     40.69%   35   34.31%
  **Hypertension**                                                                                                    
  No                                337                   66.08%                309                     75.74%   28   27.45%
  Yes                               133                   26.08%                99                      24.26%   34   33.33%
  **Surgical approach**                                                                                               
  Sweet                             236                   46.27%                198                     48.53%   38   37.25%
  Ivor-Lewis                        205                   40.20%                153                     37.50%   52   50.98%
  Mckeown                           69                    13.53%                57                      13.97%   12   11.76%
  **Margin**                                                                                                          
  Negative                          487                   95.49%                389                     95.34%   98   96.08%
  Positive                          23                    4.51%                 19                      4.66%    4    3.92%
  **Tumor location**                                                                                                  
  Upper                             45                    8.82%                 38                      9.31%    7    6.86%
  Middle                            355                   69.61%                277                     67.89%   78   76.47%
  Lower                             110                   21.57%                93                      22.79%   17   16.67%
  **Differentiation**                                                                                                 
  Well                              49                    9.61%                 37                      9.07%    12   11.76%
  Moderate                          288                   56.47%                235                     57.60%   53   51.96%
  Poor                              173                   33.92%                136                     33.33%   37   36.27%
  **T stage**                                                                                                         
  T1a                               37                    7.25%                 31                      30.39%   6    5.88%
  T1b                               66                    12.94%                52                      12.75%   14   13.73%
  T2                                111                   21.76%                90                      22.06%   21   20.59%
  T3                                255                   50.00%                206                     50.49%   49   48.04%
  T4a                               40                    7.84%                 28                      6.86%    12   11.76%
  T4b                               1                     0.20%                 1                       0.25%    0    0.00%
  **N stage**                                                                                                         
  N0                                284                   55.69%                221                     54.17%   63   61.76%
  N1                                144                   28.24%                120                     29.41%   24   23.53%
  N2                                52                    10.20%                42                      10.29%   10   9.80%
  N3                                30                    5.88%                 25                      6.13%    5    4.90%
  **AJCC-TNM stage**                                                                                                  
  IA                                11                    2.16%                 8                       1.96%    3    2.94%
  IB                                82                    16.08%                67                      16.42%   15   14.71%
  IIA                               100                   19.61%                78                      19.12%   22   21.57%
  IIB                               96                    18.82%                76                      18.63%   20   19.61%
  IIIA                              30                    5.88%                 24                      5.88%    6    5.88%
  IIIB                              149                   29.22%                121                     29.66%   28   27.45%
  IVA                               42                    8.24%                 34                      8.33%    8    7.84%
  IVB                               0                     0.00%                 0                       0.00%    0    0.00%
  **Postoperative treatment**                                                                                         
  None                              315                   61.76%                249                     61.03%   66   64.71%
  Radiation                         36                    7.06%                 33                      8.09%    3    2.94%
  Chemotherapy                      54                    10.59%                45                      11.03%   9    8.82%
  Oral chemotherapy                 28                    5.49%                 22                      5.39%    6    5.88%
  Chemoradiotherapy                 51                    10.00%                40                      9.80%    11   10.78%
  Traditional Chinese medicine      26                    5.10%                 19                      4.66%    7    6.86%
  Hospital day                      24.17±14.62           24.02±12.87           24.75±20.23                           
  Postoperative hospital day        16.48±14.90           16.29±13.23           17.24±20.32                           
  Hemoglobin (HB)(g/L)              138.91±15.28          139.11±15.10          138.12±16.03                          
  White blood cell (WBC)(10^9^/L)   6.02±1.81             6.08±1.89             5.74±1.43                             
  Lymphocyte (LY)(10^9^/L)          1.62±0.54             1.63±0.54             1.59±0.51                             
  Total protein (TP)(g/L)           69.60±6.01            69.61±5.87            69.58±6.56                            
  Albumin (ALB)(g/L)                43.81±4.47            43.92±4.44            43.36±4.58                            
  Triglyceride (TG)(mmol/L)         1.28±0.65             1.30±0.67             1.21±0.55                             
  Cholesterol (CH)(mmol/L)          4.59±0.95             4.60±0.91             4.55±1.11                             
  Fasting glucose(mmol/L)           5.04±0.90             5.03±0.92             5.09±0.79                             
  Uric acid (UA)(umol/L)            328.51±85.28          330.35±88.28          321.16±71.96                          
  Height(cm)                        166.77±6.35           166.65±6.31           167.24±6.50                           
  Weight(kg)                        61.06±9.13            60.61±9.14            62.84±8.94                            
  BMI(kg/m^2^)                      21.91±2.73            21.78±2.72            22.44±2.71                            
  Maximum diameter of tumor (cm)    3.72±1.79             3.67±1.76             3.93±1.89                             

S.D.: standard deviation.

###### 

Univariate and multivariate Cox regression analysis of the training set ESCC population.

  Variable                     Total     Event   Percentage   HR^1^(95% CI)         *P* value^1^   HR^2^(95% CI)        *P* value^2^
  ---------------------------- --------- ------- ------------ --------------------- -------------- -------------------- --------------
  Gender                                                                                                                
  Male                         355       168     47.32%       1                                    1                    
  Female                       53        11      20.75%       0.439(0.238-0.807)    0.008          0.357(0.179-0.712)   0.003
  Age(years)                   0.408                                                                                    
  ≤59                          134       67      50.00%       1                                                         
  60-69                        192       80      41.67%       0.833(0.602-1.153)    0.271                               
  ≥70                          82        32      39.02%       0.780(0.512-1.189)    0.249                               
  Alcohol                                                                                                               
  No                           146       58      39.73%       1                                                         
  Yes                          262       121     46.18%       1.163(0.850-1.590)    0.346                               
  Smoking                                                                                                               
  No                           130       44      33.85%       1                                    1                    
  Yes                          278       135     48.56%       1.435(1.021-2.016)    0.038          1.093(0.742-1.611)   0.653
  Education                                                                                                             
  Primary school and below     242       97      40.08%       1                                                         
  Middle school and above      166       82      49.40%       1.232(0.918-1.654)    0.164                               
  Hypertension                                                                                                          
  No                           309       135     43.69%       1                                                         
  Yes                          99        44      44.44%       1.017(0.724-1.430)    0.921                               
  Surgical approach            0.042             0.569                                                                  
  Sweet                        198       99      50.00%       1                                    1                    
  Ivor-Lewis                   153       66      43.14%       0.353(0.632-1.178)    0.353          0.880(0.630-1.230)   0.456
  Mckeown                      57        14      24.56%       0.491(0.281-0.860)    0.013          1.182(0.661-2.114)   0.573
  Margin                                                                                                                
  Negative                     389       166     42.67%       1                                                         
  Positive                     19        13      68.42%       1.603(0.912-2.820)    0.101                               
  Tumor location               0.485                                                                                    
  Upper                        38        15      39.47%       1                                                         
  Middle                       277       129     46.57%       1.180(0.691-2.014)    0.554                               
  Lower                        93        35      37.63%       0.953(0.521-1.746)    0.877                               
  Differentiation              0.097                                                                                    
  Well                         37        11      29.73%       1                                                         
  Moderate                     235       96      40.85%       1.374(0.736-2.564)    0.318                               
  Poor                         136       72      52.94%       1.781(0.944-3.359)    0.075                               
  T stage                      \<0.001           0.005                                                                  
  T1                           83        16      19.28%       1                                    1                    
  T2                           90        28      31.11%       2.027(1.097-3.748)    0.024          1.495(0.799-2.798)   0.209
  T3                           206       114     55.34%       3.622(2.146-6.155)    \<0.001        2.197(1.250-3.861)   0.006
  T4                           29        21      72.41%       7.509(3.906-14.434)   \<0.001        3.344(1.612-6.936)   0.001
  N stage                      \<0.001           \<0.001                                                                
  N0                           221       64      28.96%       1                                    1                    
  N1                           120       60      50.00%       2.220(1.559-3.162)    \<0.001        1.851(1.274-2.688)   0.001
  N2                           42        32      76.19%       4.674(3.045-7.174)    \<0.001        3.208(1.999-5.149)   \<0.001
  N3                           25        23      92.00%       7.514(4.623-12.212)   \<0.001        4.958(2.930-8.389)   \<0.001
  Postoperative treatment                                                                                               
  No                           249       114     45.78%       1                                                         
  Yes                          159       65      40.88%       0.981(0.722-1.322)    0.903                               
  Hemoglobin (g/L)                                                                                                      
  77-147                       277       129     46.57%       1                                                         
  148-173                      131       50      38.17%       0.822(0.593-1.139)    0.239                               
  White blood cell (10^9^/L)                                                                                            
  2.6-5.5                      182       67      36.81%       1                                    1                    
  5.6-18.1                     226       112     49.56%       1.424(1.052-1.928)    0.022          1.524(1.084-2.142)   0.015
  Lymphocyte (10^9^/L)                                                                                                  
  0.5-1.2                      101       53      52.48%       1                                    1                    
  1.3-4.0                      307       126     41.04%       0.709(0.514-0.978)    0.036          0.676(0.475-0.962)   0.030
  Total protein (g/L)                                                                                                   
  54.7-66.0                    124       60      48.39%       1                                                         
  66.1-92.1                    284       119     41.90%       0.846(0.620-1.154)    0.291                               
  Albumin (g/L)                                                                                                         
  30-49.5                      362       167     46.13%       1                                                         
  49.6-56.4                    46        12      26.09%       0.656(0.365-1.178)    0.158                               
  Triglyceride (mmol/L)                                                                                                 
  0.43-1.33                    262       130     49.62%       1                                    1                    
  1.34-6.05                    146       49      33.56%       0.618(0.445-0.859)    0.004          0.826(0.581-1.173)   0.286
  Cholesterol (mmol/L)                                                                                                  
  1.68-3.63                    172       82      47.67%       1                                                         
  3.64-8.58                    236       97      41.10%       0.842(0.628-1.130)    0.253                               
  Fasting glucose (mmol/L)                                                                                              
  2.89-4.38                    75        29      38.67%       1                                                         
  4.39-12.96                   333       150     45.05%       1.482(0.995-2.208)    0.053                               
  Uric acid (umol/L)                                                                                                    
  117-333                      228       111     48.68%       1                                    1                    
  334-684                      180       68      37.78%       0.691(0.510-0.934)    0.016          0.643(0.466-0.888)   0.007
  BMI(kg/m^2^)                                                                                                          
  15.79-20.70                  143       71      49.65%       1                                    1                    
  20.76-32.60                  265       108     40.75%       0.691(0.512-0.933)    0.016          0.908(0.661-1.247)   0.552

HR^1^ and P^1^: univariate Cox regression results.

HR^2^ and P^2^: multivariate Cox regression results.

###### 

Index categories and scores weighted by the nomogram model.

  Variable                    Category     Scores     Risk
  --------------------------- ------------ ---------- ----------
  BMI(kg/m^2^)                low(≤20.7)   7.23       Positive
  high(\>20.7)                0            Negative   
  Lymphocyte (LY)(10^9^/L)    low (≤1.2)   7.45       Positive
  high (\>1.2)                0            Negative   
  Uric acid (UA)(umol/L)      low (≤333)   6.24       Positive
  high (\>333)                0            Negative   
  Triglyceride (TG)(mmol/L)   low(≤1.33)   10         Positive
  high(\>1.33)                0            Negative   

###### 

Simplified definition of BLUT scoring tool.

  BLUT category                Score interval   Status of BMI, LY, UA and TG
  ---------------------------- ---------------- ---------------------------------------------------------------
  Normal                       0.00             No index in the positive risk category
  Low malnutrition risk        6.24-10.00       Any 1 index in the positive risk category
  Moderate malnutrition risk   13.47-17.45      Any 2 indexes in the positive risk category
  High malnutrition risk       20.92-30.92      Equal to or more than 3 indexes in the positive risk category

###### 

Univariate Cox regression analysis of PNI, CONUT, GNRI and BLUT assessment tools in ESCC patients.

  Assessment tool              Total   Event   Percentage   HR (95%CI)           *P* value^1^   *P-*value^2^
  ---------------------------- ------- ------- ------------ -------------------- -------------- --------------
  **PNI**                                                                                       0.153
  low                          97      51      52.58%       1                                   
  high                         311     128     41.16%       0.791(0.571-1.094)   0.156          
  **CONUT**                                                                      0.108          0.098
  normal                       241     98      40.66%       1                                   
  mild malnutrition            154     72      46.75%       1.142(0.842-1.548)   0.393          
  moderate malnutrition        13      9       69.23%       2.049(1.034-4.059)   0.040          
  severe malnutrition          0       0       0            NA                   NA             
  **GNRI**                                                                       0.321          0.174
  no risk                      332     138     41.57%       1                                   
  low risk                     57      30      52.63%       1.237(0.833-1.837)   0.291          
  moderate risk                17      11      64.71%       1.679(0.909-3.104)   0.098          
  major risk                   2       0       0.00%        NA                   NA             
  **BLUT**                                                                       \<0.001        \<0.001
  Normal                       50      14      28.00%       1                                   
  Low malnutrition risk        112     40      35.71%       1.302(0.708-2.394)   0.395          
  Moderate malnutrition risk   137     63      45.99%       1.849(1.036-3.300)   0.038          
  High malnutrition risk       109     62      56.88%       2.699(1.510-4.826)   0.001          

P value^1^: univariate Cox regression analysis.

P value^2^: log rank test.

###### 

Multivariate Cox regression analysis of BLUT assessment tool in ESCC patients.

  Variable                     HR (95%CI)           *P* value
  ---------------------------- -------------------- -----------
  **Gender**                                        
  Male                         1                    
  Female                       0.348(0.188-0.644)   \<0.001
  **T stage**                                       0.007
  T1                           1                    
  T2                           1.430(0.764-2.678)   0.264
  T3                           2.208(1.265-3.853)   0.005
  T4                           3.022(1.444-6.324)   0.003
  **N stage**                                       \<0.001
  N0                           1                    
  N1                           1.724(1.188-2.502)   0.004
  N2                           3.270(2.020-5.293)   \<0.001
  N3                           5.108(3.076-8.482)   \<0.001
  **BLUT category**                                 0.003
  Normal                       1                    
  Low malnutrition risk        1.211(0.655-2.240)   0.541
  Moderate malnutrition risk   1.614(0.894-2.916)   0.112
  High malnutrition risk       2.307(1.279-4.161)   0.006

###### 

Comparison of different models based on different nutritional assessment tools.

  Model                          C-index              AIC value
  ------------------------------ -------------------- -----------
  T stage+N stage                0.714(0.676-0.752)   1887.49
  T stage+N stage+PNI            0.719(0.681-0.757)   1886.48
  T stage+N stage+GNRI           0.721(0.683-0.759)   1889.00
  T stage+N stage+CONUT          0.718(0.680-0.756)   1885.56
  T stage+N stage+BLUT           0.728(0.691-0.765)   1878.35
  T stage+N stage+PNI+Gender     0.726(0.688-0.764)   1875.03
  T stage+N stage+GNRI+Gender    0.730(0.693-0.767)   1878.10
  T stage+N stage+CONUT+Gender   0.726(0.689-0.763)   1874.77
  T stage+N stage+BLUT+Gender    0.735(0.698-0.772)   1864.76
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